<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="962">
  <stage>Registered</stage>
  <submitdate>8/11/2005</submitdate>
  <approvaldate>8/11/2005</approvaldate>
  <nctid>NCT00251251</nctid>
  <trial_identification>
    <studytitle>Resynchronization/Defibrillation for Ambulatory Heart Failure Trial</studytitle>
    <scientifictitle>Resynchronization/Defibrillation for Ambulatory Heart Failure Trial</scientifictitle>
    <utrn />
    <trialacronym>RAFT</trialacronym>
    <secondaryid>FRN 63208</secondaryid>
    <secondaryid>FRN 63208</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Heart Failure, Congestive</healthcondition>
    <conditioncode>
      <conditioncode1>Cardiovascular </conditioncode1>
      <conditioncode2>Coronary heart disease</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cardiovascular </conditioncode1>
      <conditioncode2>Other cardiovascular diseases</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: devices - Optimal Medical Therapy plus ICD
Treatment: devices - Optimal Medical Therapy plus CRT/ICD

Active Comparator: 1. Optimal Medical therapy plus ICD - 

Active Comparator: 2. Optimal Medical Therapy plus CRT/ICD - 


Treatment: devices: Optimal Medical Therapy plus ICD
ICD vs CRT/ICD

Treatment: devices: Optimal Medical Therapy plus CRT/ICD
ICD vs CRT/ICD

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: devices</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Primary outcome is a composite of all cause total mortality and hospitalization for CHF</outcome>
      <timepoint>Study end</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Total mortality</outcome>
      <timepoint>Study end</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Cardiovascular mortality</outcome>
      <timepoint>Study end</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Sudden arrhythmic death</outcome>
      <timepoint>Study end</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Progressive HF death</outcome>
      <timepoint>Study end</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>All cause hospitalization rate</outcome>
      <timepoint>Study end</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>CHF hospitalization rate</outcome>
      <timepoint>Study end</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Health related quality of life</outcome>
      <timepoint>Study end</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Cost economics</outcome>
      <timepoint>Study end</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  New York Heart Association (NYHA) Class II

          -  Left ventricular ejection fraction (LVEF) less than or equal to 30% by multigated
             acquisition scan (MUGA)/catheterization OR LVEF less than or equal to 30% and LV end
             diastolic dimension = 60 mm (by echocardiogram) within 6 months prior to randomization

          -  Intrinsic QRS complex width = 120 ms OR paced QRS measurement = 200 ms

          -  ICD indication for primary or secondary prevention

          -  Optimal heart failure pharmacological therapy

          -  Normal sinus rhythm; OR chronic persistent atrial tachyarrhythmia with resting
             ventricular heart rate = 60 beats per minute (bpm) and 6 minute hall walk ventricular
             heart rate of = 90 bpm; OR chronic persistent atrial tachyarrhythmia with resting
             ventricular heart rate &gt; 60 bpm and 6 minute hall walk ventricular heart rate of &gt; 90
             bpm and booked for atrioventricular junction ablation.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Intravenous inotropic agent in the last 4 days

          -  Patients with a life expectancy of less than one year from non-cardiac cause

          -  Expected to undergo cardiac transplantation within one year (status I)

          -  In hospital patients who have acute cardiac or non-cardiac illness that requires
             intensive care

          -  Uncorrected or uncorrectable primary valvular disease

          -  Restrictive, hypertrophic, or reversible form of cardiomyopathy

          -  Severe primary pulmonary disease such as cor pulmonale

          -  Tricuspid prosthetic valve

          -  Patients with an existing ICD (patients with an existing pacemaker may be included if
             the patients satisfy all other inclusion/exclusion criteria)

          -  Coronary revascularization (coronary artery bypass graft surgery [CABG] or
             percutaneous coronary intervention [PCI]) &lt; 1 month if previously determined LVEF &gt;
             30%. Patients with a more recent revascularization can be included if a previously
             determined LVEF was = 30%.

          -  Patients with an acute coronary syndrome including myocardial infarction (MI) can be
             included if the patients have had a previous MI with LV dysfunction (LVEF = 30%).

          -  Patients included in another clinical trial that will affect the objectives of this
             study

          -  History of noncompliance to medical therapy

          -  Unable or unwilling to provide informed consent</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2>The people administering the treatment/s</masking2>
    <masking3>The people assessing the outcomes</masking3>
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate />
    <actualstartdate>1/04/2003</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>1798</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/05/2011</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <hospital>Royal Adelaide Hospital - Adelaide</hospital>
    <hospital>Sir Charles Gairdner Hospital - Perth</hospital>
    <postcode>5000 - Adelaide</postcode>
    <postcode>6009 - Perth</postcode>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Leuven</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Alberta</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>British Columbia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>New Brunswick</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Newfoundland and Labrador</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Nova Scotia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Ontario</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Quebec</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Denmark</country>
      <state>Aarhus</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Bad Berka</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Frankfurt</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Giessen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Ludwigshafen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Mainz</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Zwolle</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Turkey</country>
      <state>Izmir</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other</primarysponsortype>
    <primarysponsorname>Ottawa Heart Institute Research Corporation</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <othercollaborator>
      <othercollaboratortype>Other</othercollaboratortype>
      <othercollaboratorname>Canadian Institutes of Health Research (CIHR)</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Commercial sector/Industry</othercollaboratortype>
      <othercollaboratorname>Medtronic</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Congestive heart failure (CHF) is a common health problem that leads to frequent
      hospitalizations and an increased death rate. In spite of advances in drug therapy, it
      remains a significant public health problem. Recently, a new therapy has been developed for
      advanced heart failure patients with a ventricular conduction abnormality. This new therapy,
      called cardiac resynchronization (CRT), is a device which stimulates the atrium, the right
      ventricle, and the left ventricle providing synchronization of the contraction of the heart
      chambers. It is the addition of this therapy to an implantable cardioverter defibrillator
      (ICD) that will be evaluated in this study. This study will compare whether the implantation
      of this new therapy device, in combination with an implantable cardioverter defibrillator,
      will reduce total mortality and hospitalizations for CHF.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00251251</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Anthony Tang, MD</name>
      <address>Ottawa Heart Institute Research Corporation</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>